To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al.
作者信息
Orlandi A, Mastrantoni L, Bria E, Tortora G
机构信息
Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
出版信息
Ann Oncol. 2024 Aug;35(8):748-749. doi: 10.1016/j.annonc.2024.05.544. Epub 2024 Jun 3.
PMID:38838845
Abstract
摘要
Zotero 插件